Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer

Abemaciclib, the third CDK4/6 inhibitor, in combination with endocrine therapy shows significant benefit for the first-line treatment of HR+ HER2- advanced breast cancer.Medscape Medical News

Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news